TORNTPHARM - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 2.3
Show all parameters (20 more)
🧾 Chart Verdict
Short-term entry would be considered around 4,870 - 4,900 ₹, utilizing the support level offered by the 50 DMA and recent price action. A stop-loss order could be placed at 4,750 ₹ to mitigate risk if the stock encounters immediate resistance. An optimal exit zone would be established around 5,200 - 5,300 ₹, aligning with the previous high and potentially triggered by a breakout above the current level. Overall, the momentum appears strong, but careful monitoring of support levels is warranted given the valuation concerns.
✅ Positive
The price is currently trading above the 50 DMA and 200 DMA, indicating a bullish trend. Volume has been consistently high over the last week, suggesting strong momentum behind this move. Furthermore, the recent "Buy" rating from Univest adds positive sentiment.
⚠️ Limitation
Despite the upward trend, the very high P/E ratio of 92.1 compared to an industry PE of 34.6 suggests a potentially elevated valuation. This could create resistance at higher levels, particularly if market participants correct their enthusiasm for growth stocks. The PEG Ratio of 3.14 also indicates that the stock is overvalued relative to its expected earnings growth.
📈 Company Positive News
The "Buy" rating from Univest provides a bullish catalyst and suggests continued positive investor sentiment towards TORNTPHARM, potentially leading to further price increases.
🏭 Industry
The pharmaceutical sector is generally considered stable, but growth stocks with high P/E ratios are often sensitive to market valuations and investor confidence. Specifically, companies focused on novel therapies and specialty drugs tend to command premium valuations, reflecting their potential for significant revenue growth, which is evident here given the sharp rise in PAT.